

SECOND REGULAR SESSION

HOUSE BILL NO. 1472

95TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVES FRANZ (Sponsor), SCHAD, FLANIGAN, LARGENT,
FUNDERBURK, GRISAMORE AND WELLS (Co-sponsors).

3978L.011

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to the scheduling of 1-Pentyl-3-(1-naphthoyl)indole as a controlled substance, with penalty provisions.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

- (1) Has high potential for abuse; and
- (2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

- (1) The controlled substances listed in this subsection are included in Schedule I;
- (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
 - (a) Acetyl-alpha-methylfentanyl;
 - (b) Acetylmethadol;
 - (c) Allylprodine;
 - (d) Alphacetylmethadol;
 - (e) Alphameprodine;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 16 (f) Alphamethadol;
- 17 (g) Alpha-methylfentanyl;
- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;

52 (pp) Para-fluorofentanyl;

53 (qq) PEPAP;

54 (rr) Phenadoxone;

55 (ss) Phenampromide;

56 (tt) Phenomorphan;

57 (uu) Phenoperidine;

58 (vv) Piritramide;

59 (ww) Proheptazine;

60 (xx) Properidine;

61 (yy) Propiram;

62 (zz) Racemoramide;

63 (aaa) Thiofentanyl;

64 (bbb) Tilidine;

65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
68 is possible within the specific chemical designation:

69 (a) Acetorphine;

70 (b) Acetyldihydrocodeine;

71 (c) Benzylmorphine;

72 (d) Codeine methylbromide;

73 (e) Codeine-N-Oxide;

74 (f) Cyprenorphine;

75 (g) Desomorphine;

76 (h) Dihydromorphine;

77 (i) Drotebanol;

78 (j) Etorphine (except hydrochloride salt);

79 (k) Heroin;

80 (l) Hydromorphenol;

81 (m) Methyldesorphine;

82 (n) Methyldihydromorphine;

83 (o) Morphine methylbromide;

84 (p) Morphine methylsulfonate;

85 (q) Morphine-N-Oxide;

86 (r) Myrophine;

87 (s) Nicocodeine;

- 88 (t) Nicomorphine;
89 (u) Normorphine;
90 (v) Pholcodine;
91 (w) Thebacon;
92 (4) Any material, compound, mixture or preparation which contains any quantity of the
93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
95 the specific chemical designation:
96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
98 (c) 2,5-dimethoxyamphetamine;
99 (d) 2,5-dimethoxy-4-ethylamphetamine;
100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
101 (f) 4-methoxyamphetamine;
102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
104 (i) 3,4-methylenedioxyamphetamine;
105 (j) 3,4-methylenedioxymethamphetamine;
106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
108 (m) 3,4,5-trimethoxyamphetamine;
109 (n) Alpha-ethyltryptamine;
110 (o) Alpha-methyltryptamine;
111 (p) Bufotenine;
112 (q) Diethyltryptamine;
113 (r) Dimethyltryptamine;
114 (s) 5-methoxy-N,N-diisopropyltryptamine;
115 (t) Ibogaine;
116 (u) Lysergic acid diethylamide;
117 (v) Marijuana or marihuana;
118 (w) Mescaline;
119 (x) Parahexyl;
120 (y) Peyote, to include all parts of the plant presently classified botanically as Lophophora
121 Williamsil Lemaire, whether growing or not; the seeds thereof; any extract from any part of such
122 plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant,
123 its seed or extracts;

- 124 (z) N-ethyl-3-piperidyl benzilate;
125 (aa) N-methyl-3-piperidyl benzilate;
126 (bb) Psilocybin;
127 (cc) Psilocyn;
128 (dd) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis
129 (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
130 plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their
131 isomers with similar chemical structure and pharmacological activity to those substances
132 contained in the plant, such as the following:
- 133 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
 - 134 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
 - 135 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
 - 136 d. Any compounds of these structures, regardless of numerical designation of atomic
137 positions covered;
 - 138 (ee) Ethylamine analog of phencyclidine;
 - 139 (ff) Pyrrolidine analog of phencyclidine;
 - 140 (gg) Thiophene analog of phencyclidine;
 - 141 (hh) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
 - 142 (ii) Salvia divinorum;
 - 143 (jj) Salvinorin A;
 - 144 **(kk) 1-Pentyl-3-(1-naphthoyl)indole;**
- 145 (5) Any material, compound, mixture or preparation containing any quantity of the
146 following substances having a depressant effect on the central nervous system, including their
147 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
148 isomers is possible within the specific chemical designation:
- 149 (a) Gamma-hydroxybutyric acid;
 - 150 (b) Mecloqualone;
 - 151 (c) Methaqualone;
- 152 (6) Any material, compound, mixture or preparation containing any quantity of the
153 following substances having a stimulant effect on the central nervous system, including their
154 salts, isomers and salts of isomers:
- 155 (a) Aminorex;
 - 156 (b) N-benzylpiperazine;
 - 157 (c) Cathinone;
 - 158 (d) Fenethylamine;
 - 159 (e) Methcathinone;

- 160 (f) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
161 (g) N-ethylamphetamine;
162 (h) N,N-dimethylamphetamine;
- 163 (7) A temporary listing of substances subject to emergency scheduling under federal law
164 shall include any material, compound, mixture or preparation which contains any quantity of the
165 following substances:
- 166 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers,
167 salts and salts of isomers;
- 168 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
169 optical isomers, salts and salts of isomers;
- 170 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
171 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
172 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.
- 173 3. The department of health and senior services shall place a substance in Schedule II
174 if it finds that:
- 175 (1) The substance has high potential for abuse;
- 176 (2) The substance has currently accepted medical use in treatment in the United States,
177 or currently accepted medical use with severe restrictions; and
- 178 (3) The abuse of the substance may lead to severe psychic or physical dependence.
- 179 4. The controlled substances listed in this subsection are included in Schedule II:
- 180 (1) Any of the following substances whether produced directly or indirectly by extraction
181 from substances of vegetable origin, or independently by means of chemical synthesis, or by
182 combination of extraction and chemical synthesis:
- 183 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
184 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,
185 nalmeferne, naloxone and naltrexone, and their respective salts but including the following:
- 186 a. Raw opium;
- 187 b. Opium extracts;
- 188 c. Opium fluid;
- 189 d. Powdered opium;
- 190 e. Granulated opium;
- 191 f. Tincture of opium;
- 192 g. Codeine;
- 193 h. Ethylmorphine;
- 194 i. Etorphine hydrochloride;
- 195 j. Hydrocodone;

- 196 k. Hydromorphone;
197 l. Metopon;
198 m. Morphine;
199 n. Oxycodone;
200 o. Oxymorphone;
201 p. Thebaine;
202 (b) Any salt, compound, derivative, or preparation thereof which is chemically
203 equivalent or identical with any of the substances referred to in this subdivision, but not
204 including the isoquinoline alkaloids of opium;
205 (c) Opium poppy and poppy straw;
206 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
207 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
208 with any of these substances, but not including decocainized coca leaves or extractions which
209 do not contain cocaine or ecgonine;
210 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
211 or powder form which contains the phenanthrene alkaloids of the opium poppy);
212 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
213 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
214 the specific chemical designation, dextroprophan and levopropoxyphene excepted:
215 (a) Alfentanil;
216 (b) Alphaprodine;
217 (c) Anileridine;
218 (d) Bezitramide;
219 (e) Bulk dextropropoxyphene;
220 (f) Carfentanil;
221 (g) Butyl nitrite;
222 (h) Dihydrocodeine;
223 (i) Diphenoxylate;
224 (j) Fentanyl;
225 (k) Isomethadone;
226 (l) Levo-alphacetylmethadol;
227 (m) Levomethorphan;
228 (n) Levorphanol;
229 (o) Metazocine;
230 (p) Methadone;
231 (q) Meperidine;

- 232 (r) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
233 (s) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic
234 acid;
235 (t) Pethidine (meperidine);
236 (u) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
237 (v) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
238 (w) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
239 (x) Phenazocine;
240 (y) Piminodine;
241 (z) Racemethorphan;
242 (aa) Racemorphan;
243 (bb) Remifentanil;
244 (cc) Sufentanil;
245 (3) Any material, compound, mixture, or preparation which contains any quantity of the
246 following substances having a stimulant effect on the central nervous system:
247 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
248 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
249 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
250 (d) Phenmetrazine and its salts;
251 (e) Methylphenidate;
252 (4) Any material, compound, mixture, or preparation which contains any quantity of the
253 following substances having a depressant effect on the central nervous system, including its salts,
254 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
255 is possible within the specific chemical designation:
256 (a) Amobarbital;
257 (b) Glutethimide;
258 (c) Pentobarbital;
259 (d) Phencyclidine;
260 (e) Secobarbital;
261 (5) Any material or compound which contains any quantity of nabilone;
262 (6) Any material, compound, mixture, or preparation which contains any quantity of the
263 following substances:
264 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
265 (b) Immediate precursors to phencyclidine (PCP):
266 a. 1-phenylcyclohexylamine;
267 b. 1-piperidinocyclohexanecarbonitrile (PCC).

268 5. The department of health and senior services shall place a substance in Schedule III
269 if it finds that:

270 (1) The substance has a potential for abuse less than the substances listed in Schedules
271 I and II;

272 (2) The substance has currently accepted medical use in treatment in the United States;
273 and

274 (3) Abuse of the substance may lead to moderate or low physical dependence or high
275 psychological dependence.

276 6. The controlled substances listed in this subsection are included in Schedule III:

277 (1) Any material, compound, mixture, or preparation which contains any quantity of the
278 following substances having a potential for abuse associated with a stimulant effect on the
279 central nervous system:

280 (a) Benzphetamine;

281 (b) Chlorphentermine;

282 (c) Clortermine;

283 (d) Phendimetrazine;

284 (2) Any material, compound, mixture or preparation which contains any quantity or salt
285 of the following substances or salts having a depressant effect on the central nervous system:

286 (a) Any material, compound, mixture or preparation which contains any quantity or salt
287 of the following substances combined with one or more active medicinal ingredients:

288 a. Amobarbital;

289 b. Secobarbital;

290 c. Pentobarbital;

291 (b) Any suppository dosage form containing any quantity or salt of the following:

292 a. Amobarbital;

293 b. Secobarbital;

294 c. Pentobarbital;

295 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
296 salt;

297 (d) Chlorhexadol;

298 (e) Embutramide;

299 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
300 a drug product for which an application has been approved under Section 505 of the federal
301 Food, Drug, and Cosmetic Act;

302 (g) Ketamine, its salts, isomers, and salts of isomers;

303 (h) Lysergic acid;

- 304 (i) Lysergic acid amide;
- 305 (j) Methyprylon;
- 306 (k) Sulfondiethylmethane;
- 307 (l) Sulfonethylmethane;
- 308 (m) Sulfonmethane;
- 309 (n) Tiletamine and zolazepam or any salt thereof;
- 310 (3) Nalorphine;
- 311 (4) Any material, compound, mixture, or preparation containing limited quantities of any
- 312 of the following narcotic drugs or their salts:
- 313 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
- 314 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
- 315 of opium;
- 316 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
- 317 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
- 318 therapeutic amounts;
- 319 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
- 320 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
- 321 isoquinoline alkaloid of opium;
- 322 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
- 323 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
- 324 ingredients in recognized therapeutic amounts;
- 325 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more
- 326 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in
- 327 recognized therapeutic amounts;
- 328 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
- 329 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
- 330 ingredients in recognized therapeutic amounts;
- 331 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
- 332 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
- 333 active nonnarcotic ingredients in recognized therapeutic amounts;
- 334 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
- 335 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
- 336 amounts;
- 337 (5) Any material, compound, mixture, or preparation containing any of the following
- 338 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

339 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
340 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and
341 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is
342 expressly intended for administration through implants to cattle or other nonhuman species and
343 which has been approved by the Secretary of Health and Human Services for that administration.
344 If any person prescribes, dispenses, or distributes such steroid for human use, such person shall
345 be considered to have prescribed, dispensed, or distributed an anabolic steroid within the
346 meaning of this [paragraph] **subdivision**. Unless specifically excepted or unless listed in
347 another schedule, any material, compound, mixture or preparation containing any quantity of the
348 following substances, including its salts, esters and ethers:

- 349 (a) $3\beta,17$ -dihydroxy-5 α -androsterane;
350 (b) $3\alpha,17\beta$ -dihydroxy-5 α -androsterane;
351 (c) 5 α -androsteran-3,17-dione;
352 (d) 1-androstenediol ($3\beta,17\beta$ -dihydroxy-5 α -androster-1-ene);
353 (e) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy-5 α -androster-1-ene);
354 (f) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
355 (g) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);
356 (h) 1-androstenedione ([5 α]-androster-1-en-3,17-dione);
357 (i) 4-androstenedione (androster-4-en-3,17-dione);
358 (j) 5-androstenedione (androster-5-en-3,17-dione);
359 (k) Bolasterone (7 α , 17 α -dimethyl-17 β -hydroxyandroster-4-en-3-one);
360 (l) Boldenone (17 β -hydroxyandroster-1,4,-diene-3-one);
361 (m) Calusterone (7 β , 17 α -dimethyl-17 β -hydroxyandroster-4-en-3-one);
362 (n) Clostebol (4-chloro-17 β -hydroxyandroster-4-en-3-one);
363 (o) Dehydrochloromethyltestosterone (4-chloro-17 β -hydroxy-17 α -methyl-androst-1,
364 4-dien-3-one);
365 (p) Δ^1 -dihydrotestosterone (a.k.a. '1-testosterone')(17 β -hydroxy-5 α -androster-1-en-3-one);
366 (q) 4-dihydrotestosterone (17 β -hydroxy-androsteran-3-one);
367 (r) Drostanolone (17 β -hydroxy-2 α -methyl-5 α -androsteran-3-one);
368 (s) Ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
369 (t) Fluoxymesterone (9-fluoro-17 α -methyl-11 $\beta,17\beta$ -dihydroxyandroster-4-en-3-one);
370 (u) Formebolone (2-formyl-17 α -methyl-11 $\alpha,17\beta$ -dihydroxyandroster-1,4-dien-3-one);
371 (v) Furazabol (17 α -methyl-17 β -hydroxyandrosterano[2,3-c]-furazan);
372 (w) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
373 (x) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
374 (y) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);

- 375 (z) Mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-one);
376 (aa) Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);
377 (bb) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
378 (cc) Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
379 (dd) Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
380 (ee) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstane);
381 (ff) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane);
382 (gg) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene);
383 (hh) 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-
384 en-3-one);
385 (ii) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
386 (jj) Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);
387 (kk) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
388 (ll) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
389 (mm) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-
390 3-one) (a.k.a. '17- α -methyl-1-testosterone');
391 (nn) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
392 (oo) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
393 (pp) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
394 (qq) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
395 (rr) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
396 (ss) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
397 (tt) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
398 (uu) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
399 (vv) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
400 (ww) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
401 (xx) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
402 (yy) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);
403 (zz) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
404 (aaa) Oxymethalone (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-androstan-
405 3-one);
406 (bbb) Stanozolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
407 (ccc) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
408 (ddd) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
409 (eee) Testosterone (17 β -hydroxyandrost-4-en-3-one);
410 (fff) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);

- 411 (ggg) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
- 412 (hhh) Any salt, ester, or ether of a drug or substance described or listed in this
413 subdivision, except an anabolic steroid which is expressly intended for administration through
414 implants to cattle or other nonhuman species and which has been approved by the Secretary of
415 Health and Human Services for that administration;
- 416 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
417 United States Food and Drug Administration approved drug product;
- 418 (8) The department of health and senior services may except by rule any compound,
419 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
420 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
421 195.320 if the compound, mixture, or preparation contains one or more active medicinal
422 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
423 admixtures are included therein in combinations, quantity, proportion, or concentration that
424 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
425 the central nervous system.
- 426 7. The department of health and senior services shall place a substance in Schedule IV
427 if it finds that:
- 428 (1) The substance has a low potential for abuse relative to substances in Schedule III;
- 429 (2) The substance has currently accepted medical use in treatment in the United States;
- 430 and
- 431 (3) Abuse of the substance may lead to limited physical dependence or psychological
432 dependence relative to the substances in Schedule III.
- 433 8. The controlled substances listed in this subsection are included in Schedule IV:
- 434 (1) Any material, compound, mixture, or preparation containing any of the following
435 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
436 as set forth below:
- 437 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
438 of atropine sulfate per dosage unit;
- 439 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
440 propionoxybutane);
- 441 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
442 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
443 upon the compound, mixture or preparation valuable medicinal qualities other than those
444 possessed by the narcotic drug alone:
- 445 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
446 one hundred grams;

447 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
448 or per one hundred grams;

449 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
450 or per one hundred grams;

451 (2) Any material, compound, mixture or preparation containing any quantity of the
452 following substances, including their salts, isomers, and salts of isomers whenever the existence
453 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

- 454 (a) Alprazolam;
- 455 (b) Barbital;
- 456 (c) Bromazepam;
- 457 (d) Camazepam;
- 458 (e) Chloral betaine;
- 459 (f) Chloral hydrate;
- 460 (g) Chlordiazepoxide;
- 461 (h) Clobazam;
- 462 (i) Clonazepam;
- 463 (j) Clorazepate;
- 464 (k) Clotiazepam;
- 465 (l) Cloxazolam;
- 466 (m) Delorazepam;
- 467 (n) Diazepam;
- 468 (o) Dichloralphenazone;
- 469 (p) Estazolam;
- 470 (q) Ethchlorvynol;
- 471 (r) Ethinamate;
- 472 (s) Ethyl loflazepate;
- 473 (t) Fludiazepam;
- 474 (u) Flunitrazepam;
- 475 (v) Flurazepam;
- 476 (w) Halazepam;
- 477 (x) Haloxazolam;
- 478 (y) Ketazolam;
- 479 (z) Loprazolam;
- 480 (aa) Lorazepam;
- 481 (bb) Lormetazepam;
- 482 (cc) Mebutamate;

- 483 (dd) Medazepam;
484 (ee) Meprobamate;
485 (ff) Methohexital;
486 (gg) Methylphenobarbital (mephobarbital);
487 (hh) Midazolam;
488 (ii) Nimetazepam;
489 (jj) Nitrazepam;
490 (kk) Nordiazepam;
491 (ll) Oxazepam;
492 (mm) Oxazolam;
493 (nn) Paraldehyde;
494 (oo) Petrichloral;
495 (pp) Phenobarbital;
496 (qq) Pinazepam;
497 (rr) Prazepam;
498 (ss) Quazepam;
499 (tt) Temazepam;
500 (uu) Tetrazepam;
501 (vv) Triazolam;
502 (ww) Zaleplon;
503 (xx) Zolpidem;
504 (yy) Zopiclone;
505 (3) Any material, compound, mixture, or preparation which contains any quantity of the
506 following substance including its salts, isomers and salts of isomers whenever the existence of
507 such salts, isomers and salts of isomers is possible: fenfluramine;
508 (4) Any material, compound, mixture or preparation containing any quantity of the
509 following substances having a stimulant effect on the central nervous system, including their
510 salts, isomers and salts of isomers:
511 (a) Cathine ((+)-norpseudoephedrine);
512 (b) Diethylpropion;
513 (c) Fencamfamin;
514 (d) Fenproporex;
515 (e) Mazindol;
516 (f) Mefenorex;
517 (g) Modafinil;
518 (h) Pemoline, including organometallic complexes and chelates thereof;

- 519 (i) Phentermine;
- 520 (j) Pipradrol;
- 521 (k) Sibutramine;
- 522 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
- 523 (5) Any material, compound, mixture or preparation containing any quantity of the
- 524 following substance, including its salts:
- 525 (a) butorphanol;
- 526 (b) pentazocine;
- 527 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance
- 528 is the only active medicinal ingredient;
- 529 (7) The department of health and senior services may except by rule any compound,
- 530 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
- 531 subsection from the application of all or any part of sections 195.010 to 195.320 if the
- 532 compound, mixture, or preparation contains one or more active medicinal ingredients not having
- 533 a depressant effect on the central nervous system, and if the admixtures are included therein in
- 534 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
- 535 substances which have a depressant effect on the central nervous system.
- 536 9. The department of health and senior services shall place a substance in Schedule V
- 537 if it finds that:
- 538 (1) The substance has low potential for abuse relative to the controlled substances listed
- 539 in Schedule IV;
- 540 (2) The substance has currently accepted medical use in treatment in the United States;
- 541 and
- 542 (3) The substance has limited physical dependence or psychological dependence liability
- 543 relative to the controlled substances listed in Schedule IV.
- 544 10. The controlled substances listed in this subsection are included in Schedule V:
- 545 (1) Any compound, mixture or preparation containing any of the following narcotic
- 546 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
- 547 forth below, which also contains one or more nonnarcotic active medicinal ingredients in
- 548 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
- 549 qualities other than those possessed by the narcotic drug alone:
- 550 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
- 551 twenty-five micrograms of atropine sulfate per dosage unit;
- 552 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
- 553 one hundred grams;

554 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
555 micrograms of atropine sulfate per dosage unit;

556 (2) Any material, compound, mixture or preparation which contains any quantity of the
557 following substance having a stimulant effect on the central nervous system including its salts,
558 isomers and salts of isomers: pyrovalerone;

559 (3) Any compound, mixture, or preparation containing any detectable quantity of
560 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
561 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
562 isomers, or salts of optical isomers;

563 (4) Unless specifically exempted or excluded or unless listed in another schedule, any
564 material, compound, mixture, or preparation which contains any quantity of the following
565 substances having a depressant effect on the central nervous system, including its salts:
566 pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].

567 11. If any compound, mixture, or preparation as specified in subdivision (3) of
568 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a
569 prescription:

570 (1) All packages of any compound, mixture, or preparation containing any detectable
571 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,
572 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind
573 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or
574 registered pharmacy technician; and

575 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
576 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,
577 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers
578 shall be at least eighteen years of age; and

579 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require
580 any person, prior to their purchasing, receiving or otherwise acquiring such compound, mixture,
581 or preparation to furnish suitable photo identification that is issued by a state or the federal
582 government or a document that, with respect to identification, is considered acceptable and
583 showing the date of birth of the person;

584 (4) The seller shall deliver the product directly into the custody of the purchaser.

585 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
586 implement and maintain an electronic log of each transaction. Such log shall include the
587 following information:

588 (1) The name, address, and signature of the purchaser;

589 (2) The amount of the compound, mixture, or preparation purchased;

- 590 (3) The date and time of each purchase; and
591 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
592 technician who dispensed the compound, mixture, or preparation to the purchaser.
- 593 13. Each pharmacy shall submit information regarding sales of any compound, mixture,
594 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with
595 transmission methods and frequency established by the department by regulation;
- 596 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
597 greater than those specified in this chapter.
- 598 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products
599 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter
600 where the public is not permitted.
- 601 16. Any person who knowingly or recklessly violates the provisions of subsections 11
602 to 15 of this section is guilty of a class A misdemeanor.
- 603 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this
604 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,
605 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,
606 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must
607 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.
- 608 18. The manufacturer of a drug product or another interested party may apply with the
609 department of health and senior services for an exemption from this section. The department of
610 health and senior services may grant an exemption by rule from this section if the department
611 finds the drug product is not used in the illegal manufacture of methamphetamine or other
612 controlled or dangerous substances. The department of health and senior services shall rely on
613 reports from law enforcement and law enforcement evidentiary laboratories in determining if the
614 proposed product can be used to manufacture illicit controlled substances.
- 615 19. The department of health and senior services shall revise and republish the schedules
616 annually.
- 617 20. The department of health and senior services shall promulgate rules under chapter
618 536, RSMo, regarding the security and storage of Schedule V controlled substances, as described
619 in subdivision (3) of subsection 10 of this section, for distributors as registered by the department
620 of health and senior services.
- 621 21. Logs of transactions required to be kept and maintained by this section and section
622 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is
623 the person whose transactions are recorded in the logs.

✓